3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Completed
3
Sponsor Class
INDUSTRY
3
OTHER
2
Study Type
Interventional
3
Expanded_access
1
Sponsor
Cancer Type
CNS
3
Sarcoma
2
Conditions
Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Brain Neoplasms
2
Recurrence
1
Glioma
1
Interventions
pembrolizumab
1023
Carboplatin
964
Paclitaxel
933
Gemcitabine
794
Cisplatin
751
Docetaxel
683
Bevacizumab
609
Pemetrexed
502
Nivolumab
487
Cyclophosphamide
471
Capecitabine
461
Fluorouracil
418
Dexamethasone
403
Rituximab
372
Oxaliplatin
348
Injections
345
atezolizumab
298
Trastuzumab
298
Leucovorin
288
Cetuximab
282
Irinotecan
268
130-nm albumin-bound paclitaxel
254
Prednisone
245
Doxorubicin
240
Ipilimumab
226
Lenalidomide
220
fludarabine
218
Fulvestrant
217
durvalumab
205
Erlotinib Hydrochloride
188
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
rindopepimut
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled
NCT00458601
2018-01-16
ACT III
Celldex Therapeutics
Phase 2
Completed
82 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled